Disc Medicine raises $450 million through an enlarged share sale

what happened

Clinical-stage biopharma Disc Medicine has set final pricing for an enlarged public share sale. The company will sell 6 million common shares at $75 apiece, which would bring gross proceeds to about $450 million before underwriting discounts, commissions and other costs. GlobeNewswire published the announcement on October 20, 2026, and Reuters carried the pricing news.

Underwriters received a 30-day option to buy up to 900,000 more shares at the same price, net of discounts and commissions. Closing is expected on October 22, 2026, subject to standard conditions.

Proceeds, combined with existing cash and securities, will go toward research and clinical development of current and new candidates, preparing commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), other pre-commercial work and general working capital. Jefferies, Leerink Partners, Morgan Stanley and Cantor are joint bookrunners.

why it matters

For investors, the deal adds substantial capital to a company developing treatments for serious blood disorders that has not yet reached commercial scale. Issuing shares on this scale typically dilutes existing holders, so the effect mainly concerns DISC shareholders rather than the broader market.

tags

instruments